Specialty pharmaceutical company
Providing solutions to unmet medical needs.
Shield Therapeutics is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru®
Find out moreOur clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make the difference in their everyday lives.
Shield Therapeutics is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru®
Find out moreAccrufer®/Feraccru® is a novel oral product that addresses the needs of patients who cannot tolerate existing oral iron products and offers a clear alternative to IV iron therapy.
Find out moreThe content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.
RT @Edison_Inv_Res: @ShieldTx reported FY21 results in line with market expectations, recording revenue of £1.5m, including a maiden £0.1m…
RT @proactive_UK: $STX Shield Therapeutics off to a solid start in 2022 with Acrrufer prescriptions rising sharply https://t.co/p3ljd5XejC…
RT @WalbrookPR: Shield Therapeutics plc (AIM: #STX, @ShieldTx) Business Update 📈100%⬆️total Accrufer prescriptions in Q1-22 🇺🇸100m/40% of…